한글목차

세계의 피부사상균성 조진균증 치료 시장은 2030년까지 106억 달러에 달할 전망

2023년에 75억 달러로 추정되는 세계의 피부사상균성 조진균증 치료 시장은 2023-2030년 CAGR 5.1%로 성장하며, 2030년에는 106억 달러에 달할 것으로 예측됩니다. 본 리포트에서 분석한 부문의 하나인 국소 요법은 CAGR 6.1%를 기록하며, 분석 기간 종료시에는 71억 달러에 달할 것으로 예측됩니다. 전신 요법 분야의 성장률은 분석 기간 중 CAGR 3.3%로 추정됩니다.

미국 시장은 20억 달러로 추정, 중국은 CAGR 4.8%로 성장 예측

미국의 피부사상균성 조진균증 치료 시장은 2023년에 20억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 17억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2023-2030년 CAGR은 4.8%입니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 5.0%와 3.9%로 예측됩니다. 유럽에서는 독일이 CAGR 4.1%로 성장할 것으로 예측됩니다.

세계의 피부사상균성 조진균증 치료 시장 - 주요 동향과 촉진요인 정리

피부사상균성 조진균증이란 무엇인가?

피부사상균성 조진균증은 일반적으로 손발톱 진균이라고 불리며, 주로 발톱을 침범하는 진균 감염입니다. 피부사상균은 따뜻하고 습한 환경에서 번식하는 진균의 일종으로, 발톱은 신발 안에 있는 경우가 많기 때문에 좋은 표적이 될 수 있습니다. 손발톱이 두꺼워지고, 변색되고, 갈라지는 것이 특징인 이 증상은 상당한 통증을 동반할 수 있으며, 종종 큰 불편함과 당혹감을 유발할 수 있습니다. 조진균증의 유병률은 특히 노인, 당뇨병 환자, 면역력이 저하된 사람에서 높은데, 이들은 혈액 순환이 좋지 않고 손톱의 성장이 저하되어 위험이 더 높습니다. 치료는 미용상의 이유뿐만 아니라 다른 손톱으로 감염이 퍼지거나 다른 사람에게 더 심각한 감염을 예방하는 데에도 매우 중요합니다. 이 상태를 효과적으로 관리하려면 약리학적 치료와 경우에 따라 외과적 개입을 결합해야합니다.

조진균증에 대한 현재 치료법은 어떻게 발전하고 있는가?

피부사상균성 조진균증의 치료법은 지난 10년간 크게 발전하여 보다 효과적이고 덜 침습적인 치료법으로 전환되고 있습니다. 기존에는 항진균제를 복용하여 치료했지만, 항진균제는 효과적이지만 간 손상, 피부 발진 등의 심각한 부작용이 발생할 수 있고, 혈액 검사를 통한 정기적인 모니터링이 필요했습니다. 외용 치료제는 더 안전하지만 일반적으로 효과가 낮고 특히 심각한 감염에 효과적입니다. 최근 개발되고 있는 새로운 치료법은 더 효율적인 외용제, 부작용이 적은 개선된 내복약, 레이저 및 광역학 치료와 같은 새로운 치료법이 개발되고 있습니다. 이러한 새로운 치료법은 곰팡이를 보다 직접적으로 표적으로 삼기 때문에 치료 기간을 단축하고 부작용을 최소화하면서 효능을 향상시킬 수 있습니다. 또한 보다 덜 자극적인 치료법을 원하는 환자들에게 매력적인 자연 요법 및 대체 요법에 대한 관심도 증가하고 있습니다.

치료 성과 향상에 있으며, 기술의 역할은 무엇인가?

기술 혁신은 피부사상균성 조진균증의 진단과 치료 개선에 매우 중요한 역할을 하고 있습니다. 빛 간섭 단층촬영과 같은 첨단 영상 진단 기술은 감염 범위를 보다 정확하게 가시화하여 보다 정밀한 치료를 가능하게 합니다. 또한 레이저 치료의 개발은 조진균증 관리에 새로운 국면을 가져와 전신 치료에 따른 부작용 없이 빠르고 안전하며 반복 가능한 치료 옵션을 제공하게 되었습니다. 이 레이저는 손톱을 관통하여 주변 손톱과 피부를 손상시키지 않고 열로 곰팡이를 파괴하여 효과를 발휘합니다. 또한 외용 치료제의 전달 메커니즘에 대한 지속적인 연구로 그 효능이 향상되고 있습니다. 예를 들어 현재 손톱의 딱딱한 외부 표면에 쉽게 침투할 수 있는 새로운 형태의 약물이 개발되고 있습니다. 이러한 기술의 발전은 환자의 치료 결과를 개선할 뿐만 아니라 치료 프로토콜의 전반적인 효율성을 향상시키고 있습니다.

피부사상균성 조진균증 치료 시장의 성장 원동력은?

피부사상균성 손발톱진균증 치료제 시장의 성장은 면역력 저하와 혈액순환 악화로 인해 진균 감염에 취약한 고령화 등 여러 요인에 의해 발생합니다. 인식의 향상과 진단 기술의 발전도 치료율 향상에 기여하고 있습니다. 또한 헬스장, 수영장, 스파 등 공용 공간에 더 많이 노출되는 라이프스타일의 변화도 진균 감염증 발생률 증가에 영향을 미치고 있습니다. 보다 새롭고 효과적이며 안전한 치료법 개발과 미적 외관에 대한 선호도가 높아지면서 고급 조진균증 치료에 대한 수요를 촉진하고 있습니다. 의료 서비스 프로바이더들이 보다 효율적이고 환자 친화적인 치료법을 지속적으로 모색함에 따라 약리학 및 기술 분야의 지속적인 혁신과 개선이 시장 성장의 원동력이 되어 시장이 확대될 것으로 예상됩니다.

조사 대상 기업의 예(총 44건)

• Allergan PLC
• Galderma SA
• GlaxoSmithKline PLC
• Johnson & Johnson
• Moberg Pharma AB
• NovaBiotics Ltd
• Novartis AG
• Pfizer, Inc.
• Sanofi SA
• Valeant Pharmaceuticals International, Inc.

목차

제1장 조사 방법

제2장 개요

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 세계 시장의 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 기타 유럽
• 아시아태평양
• 기타 지역

제4장 경쟁

영문목차

Global Dermatophytic Onychomycosis Treatment Market to Reach US$10.6 Billion by 2030

The global market for Dermatophytic Onychomycosis Treatment estimated at US$7.5 Billion in the year 2023, is expected to reach US$10.6 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2023-2030. Topical Therapy, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$7.1 Billion by the end of the analysis period. Growth in the Systemic Therapy segment is estimated at 3.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.0 Billion While China is Forecast to Grow at 4.8% CAGR

The Dermatophytic Onychomycosis Treatment market in the U.S. is estimated at US$2.0 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 4.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.0% and 3.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Dermatophytic Onychomycosis Treatment Market - Key Trends and Drivers Summarized

What Is Dermatophytic Onychomycosis and Why Is It a Concern?

Dermatophytic onychomycosis, commonly referred to as toenail fungus, involves a fungal infection that affects the nails, primarily the toenails. It is caused by dermatophytes, a type of fungus that thrives in warm, moist environments, making toenails a prime target due to their frequent enclosure in shoes. This condition is characterized by thickening, discoloration, and splitting of the nail, and can be quite painful, often leading to significant discomfort and embarrassment. The prevalence of onychomycosis is particularly high among the elderly, diabetic, and those with compromised immune systems, who are at greater risk due to poorer circulation and reduced nail growth. Treatment is crucial not only for cosmetic reasons but also to prevent the spread of the infection to other nails or, more seriously, to other individuals. Effective management of the condition requires a combination of pharmacological treatments and, in some cases, surgical intervention.

How Are Current Treatments Evolving in the Fight Against Onychomycosis?

The treatment landscape for dermatophytic onychomycosis has evolved significantly over the past decade, with a shift towards more effective and less invasive options. Traditionally, the approach has included oral antifungal medications, which are effective but can have serious side effects, such as liver damage or skin rashes, necessitating regular monitoring with blood tests. Topical treatments are safer but generally less effective, especially for more severe infections. Recent advancements have led to the development of more efficient topical solutions, improved oral medications with fewer side effects, and novel treatment modalities like laser and photodynamic therapy. These newer methods target the fungus more directly, potentially reducing treatment duration and improving efficacy with minimal side effects. Additionally, there is a growing interest in the use of natural and alternative remedies, which appeal to patients seeking less harsh treatment options.

What Role Does Technology Play in Enhancing Treatment Outcomes?

Innovations in technology are playing a pivotal role in improving the diagnosis and treatment of dermatophytic onychomycosis. Advanced imaging techniques, such as optical coherence tomography, allow for more accurate visualization of the infection extent, facilitating more targeted treatments. Additionally, the development of laser therapy has introduced a new dimension to onychomycosis management, offering a quick, safe, and repeatable treatment option without the side effects associated with systemic therapies. These lasers work by penetrating the nail and destroying the fungi with heat without damaging the surrounding nail or skin. Moreover, ongoing research into the delivery mechanisms of topical treatments is enhancing their effectiveness; for example, new forms of medication that can better penetrate the nail's hard exterior are currently being developed. This technological progress not only improves patient outcomes but also enhances the overall efficiency of treatment protocols.

What Drives the Growing Market for Dermatophytic Onychomycosis Treatment?

The growth in the dermatophytic onychomycosis treatment market is driven by several factors, including an aging global population, which is more susceptible to fungal infections due to decreased immunity and poor blood circulation. Increased awareness and better diagnostic techniques are also contributing to higher treatment rates. Furthermore, lifestyle changes that increase exposure to communal areas such as gyms, pools, and spas are leading to a higher incidence of fungal infections. The development of newer, more effective, and safer treatments, along with a rising preference for aesthetic appearance, is fueling demand for advanced onychomycosis treatments. As healthcare providers continue to seek more efficient and patient-friendly treatment options, the market is expected to expand, with continued innovations and improvements in both pharmacological and technological domains driving growth further.

Select Competitors (Total 44 Featured) -

• Allergan PLC
• Galderma SA
• GlaxoSmithKline PLC
• Johnson & Johnson
• Moberg Pharma AB
• NovaBiotics Ltd
• Novartis AG
• Pfizer, Inc.
• Sanofi SA
• Valeant Pharmaceuticals International, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Dermatophytic Onychomycosis Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
  • Global Economic Update
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of Diabetes Bolsters Demand for Onychomycosis Treatment
  • Advances in Antifungal Therapies Propel Market Growth
  • Increased Awareness of Foot Health Drives Adoption of Treatments
  • Growing Elderly Population Sustains Demand for Effective Onychomycosis Solutions
  • Expansion of Over-the-Counter Antifungal Products Generates Greater Consumer Access
  • The Role of Podiatrists and Dermatologists in Driving Treatment Adoption
  • Telemedicine and Online Consultations Expand Patient Reach
  • Growing Demand for Natural and Alternative Treatment Options
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Dermatophytic Onychomycosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 3: World 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Systemic Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Systemic Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 6: World 16-Year Perspective for Systemic Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Topical Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Topical Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 9: World 16-Year Perspective for Topical Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Device-based Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Device-based Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 12: World 16-Year Perspective for Device-based Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 15: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Dermatology Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Dermatology Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 18: World 16-Year Perspective for Dermatology Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 21: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 23: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 24: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 25: World Dermatophytic Onychomycosis Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Dermatophytic Onychomycosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Canada 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030
• JAPAN
  • Dermatophytic Onychomycosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Japan 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: Japan 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030
• CHINA
  • Dermatophytic Onychomycosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 44: China Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: China 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
  • TABLE 47: China Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: China 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030
• EUROPE
  • Dermatophytic Onychomycosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Dermatophytic Onychomycosis Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030
• FRANCE
  • Dermatophytic Onychomycosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 59: France Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: France 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
  • TABLE 62: France Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: France 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030
• GERMANY
  • Dermatophytic Onychomycosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: Germany 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: Germany 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Italy 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Italy 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Dermatophytic Onychomycosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 77: UK Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: UK 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
  • TABLE 80: UK Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: UK 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Rest of Europe Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: Rest of Europe 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
  • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Rest of Europe Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: Rest of Europe 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Dermatophytic Onychomycosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Asia-Pacific Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: Asia-Pacific 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
  • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Asia-Pacific Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Asia-Pacific 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Rest of World Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Rest of World 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
  • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Rest of World Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Rest of World 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION